NewsBenzingaセレノーム、再発性膠芽腫におけるREYOBIQの第2相ReSPECT-GBM試験の登録を完了;トップラインデータは2027年半ばに予定 セレノーム、再発性膠芽腫におけるREYOBIQの第2相ReSPECT-GBM試験の登録を完了;トップラインデータは2027年半ばに予定 Benzinga 2026.10.29 12:24 (GMT+0) Open on Benzinga Other news AECOM Hikes Dividend, Backlog Hits Record $28 Billion Elon Musk Steps in After Jensen Huang Loses X Verification Following Nvidia Exit: ‘Blue Check Coming Back for Free on the House’ 'US Gas Pump Price Hits Lowest Since March as Oil Supply Recovers' - Bloomberg Trump Backs Howard Lutnick Amid Nvidia Row, Says Restrictions Could Have Triggered China Showdown: ‘I Understand Both Sides of It’ Amazon Cranks Up Its India Clean Energy Investment With Fresh $7 Billion Bet OpenAI Faces California Lawsuit Over 80 Rogue AI Incidents as AG Rob Bonta Warns Known Cyberattacks May Be ‘Tip of the Iceberg'
Elon Musk Steps in After Jensen Huang Loses X Verification Following Nvidia Exit: ‘Blue Check Coming Back for Free on the House’
Trump Backs Howard Lutnick Amid Nvidia Row, Says Restrictions Could Have Triggered China Showdown: ‘I Understand Both Sides of It’
OpenAI Faces California Lawsuit Over 80 Rogue AI Incidents as AG Rob Bonta Warns Known Cyberattacks May Be ‘Tip of the Iceberg'